期刊文献+

探讨三维适行放射治疗在晚期胰腺癌中的临床意义 被引量:5

Clinical significance of three-dimensional conformal technique treatment for locally advanced pancreatic cancer
下载PDF
导出
摘要 目的探讨三维适形放射治疗对局部晚期胰腺癌的疗效。方法将26例局部晚期胰腺癌患者随机分成治疗组13例,对照组13例。治疗组使用三维适形放射治疗,单次肿瘤剂量2-4 Gy,总剂量可达50-54 Gy。单次剂量2-2.5 Gy时一周5次;单次剂量3.5-4 Gy时一周3次。对照组使用常规放射治疗。两组总剂量及分割剂量相同,分割剂量2 Gy。结果治疗组和对照组放射治疗后1个月疼痛缓解分别为11例和7例(χ2=11.56,P<0.01);体重增加分别为10例和7例(χ2=6.12,P<0.05);Karnofsky评分上升分别为8例和5例(χ2=5.54,P<0.05)。治疗组和对照组病灶缓解情况分别为84.6%和53.8%(χ2=7.04,P<0.01),毒副反应率分别为15.4%和46.2%(χ2=6.48,P<0.05),1年生存率分别为61.5%和38.5%(χ2=5.54,P<0.05)。结论三维适形放射治疗局部晚期胰腺癌,能提高患者的生存质量,延长生存期。 Objective To investigate the efficacy of three-dimensional conformal radiation therapy for locally advanced pancreatic cancer.Methods 26 patients with locally advanced pancreatic cancer were randomly divided into treatment group 13 cases,13 cases in the control group.The paitents of treatment group were used the three-dimensional conformal radiation therapy,a single tumor dose of 2-4 Gy,total dose up to 50~54 Gy.2~2.5 Gy single dose,five times a week;3.5~4 Gy single dose,three times a week.The paitents of control group were used conventional radiation therapy.There was the same the total dose and split dose in two groups,split dose 2 Gy.Results There were different in a pain response rate respectively 11 cases and 7 cases(χ2 = 11.56,P 0.01),weight gain respectively 10 cases and 7 cases(χ2 = 6.12,P 0.05),increase in Karnofsky performance score respectively 8 cases and 5 cases(χ2 = 5.54,P 0.05),lesions to defuse the situation respectively 84.6% and 53.8%(χ2 =7.04,P 0.01),toxicity respectively 15.4% and 46.2%(χ2 = 6.48,P 0.05) and 1 year survival rate respectively 61.5% and 38.5%(χ2 = 5.54,P 0.05) after radiotherapy in treatment and control groups.Conclusion Three-dimensional conformal radiation therapy can improve patient quality of life and prolong survival in locally advanced pancreatic cancer.
出处 《中国医药导报》 CAS 2012年第35期75-76,80,共3页 China Medical Herald
关键词 胰腺肿瘤 放射疗法 适形放疗 疗效 Pancreatic neoplasms Radiotherapy Conformal radiotherapy Efficacy
  • 相关文献

参考文献8

二级参考文献40

  • 1AShankar,RCGRussell.Recent advances in the surgical treatment of pancreatic cancer[J].World Journal of Gastroenterology,2001,7(5):622-626. 被引量:19
  • 2张蓓,朱立勤.乳腺癌药物治疗的研究进展[J].中国药物与临床,2004,4(8):616-619. 被引量:5
  • 3虞先浚,蒋永剑,傅德良,倪泉兴.胰腺癌中胸苷磷酸化酶和二氢嘧啶脱氢酶含量及其比值的测定[J].中华肿瘤杂志,2004,26(10):618-620. 被引量:9
  • 4李兆申.胰腺癌研究进展[J].中国实用内科杂志:临床前沿版,2006,26(12):1921-1923. 被引量:6
  • 5Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997,15 (6):2403-2413.
  • 6Fung MC, Ishiguro H, Takayama S, et al. Survival benefit of chemotherapy treatment in advanced pancreatic cancer: A meta-analysis [R]. Proceeding of the ASCO, 2003:1155a.
  • 7Heinemann V, Hinke A, Bsck S, et al. Gemeitabinebased combinations (gem+x) vs gemeitabine (gem) alone in the treatment of advaneed panereatie eaneer: a meta-analysis of sixteen randomized trials [J]. Journal of Clinical Oneology,2007,25(18S):4515.
  • 8Yang Q, Xie DR, Liang HL, randomized controlled trials (GEM)-based combination et al. A meta-analysis of comparing gemcitabine chemotherapy with gemcitabine alone in advanced pancreatic cancer: An updated subgroup analysis of overall survival [J]. J Clin Oncol 2008,26(suppl): 15661.
  • 9Moore MJ, Goldstein D, Hamm J, el al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group [J]. J Clin Oncol,2007,25(15):1960-1966.
  • 10Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase Ⅲ study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study [J]. Journal of Clinical Oncology,2007,25 (85S):LBA4509.

共引文献62

同被引文献53

  • 1戴月娣,张德祥,袁苏徐,陶莉.胰腺癌治疗方式评价及预后分析[J].中国癌症杂志,2011,21(3):211-215. 被引量:11
  • 2卞文安.CA19-9检测在胰腺癌临床诊断中的意义[J].新疆医学,2006,36(4):13-14. 被引量:2
  • 3Joensuu TK,Kiviluoto T,Karkkainen P,et al. Phase I-II trial of twice weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer[J]. International Journal of Radiation Oncology Biology Physics, 2004,60(2):444-452.
  • 4Coley SC,Strickland NH,Walker JD,et al. Spiral CT and the pre operative assessment of pancreatic adenocarcinoma [J]. Clinical Radiology, 1997,52 ( 1 ) : 24-30.
  • 5Tanaka N,Okada S, Ueno H,et al. The usefulness of serial changes in serum CA19 9 levels in the diagnosis of pancreatic caneer[J]. Pancreas, 2000,20 (4) : 378-381.
  • 6Small Jr W,Mulcahy MF,RademaKer A,et at. Ptaase II thai of full-dose gemcitabine and bevaeizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer [J].International Journal of Radiation Oncology Biology Physics, 2011,80 (2) : 476-482.
  • 7Huguet F, Goodman KA, Azria D, et al. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations[J]. International Journal of Radiation Oncology Biology Physics,2012,83(5) :1355-1364.
  • 8Girgis MD, Federman N, Rochefort MM, et al. An engineered anti-CA19-9 eys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanopartieles[J]. J Surg Res,2013,185(1) :45 -55.
  • 9Wu E,Zhou S,Bhat K,et al. CA19 9 and Pancreatic Cancer [J]. Clinical Advances In Hematology & Oncology, 2013,11 (1) :53-55.
  • 10Lee KJ,Yi SW,Chung MJ,et al. Serum CA 19 9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma [J]. Yonsei Medical Journal,2013,54(3):643-649.

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部